| |
 |
|
| With specialized resources and expertise, contract research outsourcing (CRO) services usually offer more efficient studies in especially early stage of drug discovery than Sponsor companies in terms of timeline and cost, enabling |
|
better management of discovery risk and taking advantages of ¡°kill fast, kill early¡± as to early stage of screening. Meanwhile CRO strategy also ensures that more promising compounds are advanced into a company's pipeline. Especially at present, as pricing pressures in biotechnology markets increase, biological research outsourcing becomes one of major strategies for both academic and industrial researches.
Shanghai Genomics (SG), located at Zhangjiang Hi-Tech Park Shanghai, was initially founded in 2001 by returnees from the US biotech industry and combined later in 2005 with GNI, Ltd., an international pharmaceutical development company headquartered in Tokyo, Japan, which went public on the Tokyo Stock Exchange on August 31, 2007 (TSE MOTHERS: 2160). SG is aiming to become a major player in the fragmented Chinese
 |
pharmaceutical industry. Shanghai Genomics has built an integrated drug discovery platform. The company¡¯s technology platform includes stable cell line generation, protein expression and purification, antibody production, signalling pathway mapping, gene expression profiling, and animal modeling. Internal discoveries have been published on some top biology journals like PNAS and FEBS Letters etc. The company leverages this highly efficient and low-cost platform to provide collaboration/contract research services for global partners from both academic and biotech or pharmaceutical field. |
With years of development, SG has established good relationship with quite some leading pharmas and research institutes. Collaboration increased year by year all over the world. With its well-trained technical staff and outstanding research capabilities Shanghai Genomics has received extensive coverage by worldwide media organizations, such as the Wall Street Journal, Asian Wall Street Journal and many other well-known media groups in China. We believe that the company¡¯s complementary platforms, advanced technologies and instruments, highly efficient research group, and modern management approach ensures a promising future for the company
|
|
|
